Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial

International Journal of Clinical Oncology, 04/18/2012

Simultaneous administration of zoledronic acid (ZOL) and maximal androgen blockade (MAB) as initial treatment delayed time to progression (TTP) in bone–metastatic prostate cancer patients. Initial treatment with ZOL has the possibility of anti–tumor activity to delay disease progression.

Print Article Summary

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List